Evidence map›Paper›PMID 41910414›Full record

ArticleThe FEBS journal2026

Mechanistic insights into HapC: A key enzyme in prodiginine biosynthesis in Hahella chejuensis.

Yueh-Te Chan, Aden Dhana Rizkita, Hsin-Ju Hsieh, Shu-Fang Hsu, Tony Eight Lin, Wei-Jan Huang, Kai-Cheng Hsu, Sheila Nathan, Peiching Chang, Andrew H-J Wang and 1 more

Abstract read
In one paragraph

Article in The FEBS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yueh-Te ChanThe Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taiwan.
Aden Dhana RizkitaSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taiwan.
Hsin-Ju HsiehDepartment of Water System Development and Application Research, Division of Water Technology, Industrial Technology Research Institute, Hsinchu, Taiwan.
Shu-Fang HsuThe Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taiwan.
Tony Eight LinGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taiwan.
Wei-Jan HuangSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taiwan.
Kai-Cheng HsuGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taiwan.
Sheila NathanFaculty of Science and Technology, Department of Biological Sciences and Biotechnology, Universiti Kebangsaan Malaysia, Bangi, Selangor, Malaysia.
Peiching ChangMaterial and Chemical Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan.
Andrew H-J WangThe Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taiwan.ORCID https://orcid.org/0000-0002-0016-5337
Cheng-Chung LeeThe Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taiwan.ORCID https://orcid.org/0000-0002-8259-4388

Funding

National Science and Technology Council 113-2314-B-038-134National Science and Technology Council 113-2314-B-038-135National Science and Technology Council 113-2320-B-038-022-MY3National Science and Technology Council 113-2320-B-038-026National Science and Technology Council 113-2811-B-038-007
6 · The paper itself

Abstract

Research to understand the enzymatic machinery underlying the biosynthesis of red prodigiosin, a potent secondary metabolite with significant biological activity, led to the identification of HapC, an enzyme from the marine bacterium Hahella chejuensis. In this study, we demonstrated the catalytic capability of HapC in synthesizing a diverse array of short-chain prodiginines through the condensation of various 2-methyl-3-amylpyrrole (MAP) analogs with 4-methoxy-2,2'-bipyrrole-5-carboxaldehyde (MBC). Six prodiginines, all non-native to HapC, were enzymatically synthesized in vitro, including two analogs, 3,4-dimethyl-6-methoxyprodiginine and 2-ethyl-6-methoxyprodiginine, that have not been successfully produced by any prodigiosin-forming enzyme to date, demonstrating the subtle differences in the products formed by HapC. Constructing a structural model of HapC and performing ligand docking simulations with representative ligands corresponding to different reaction steps, including an ATP analog, a phosphorylated MBC, and a prodiginine product, revealed catalytic residues in the two active sites of HapC. To extend from local catalytic interactions to the global mechanistic level, a comparative structural analysis with the homologous rifampin phosphotransferase from Listeria monocytogenes was applied to infer domain dynamics in HapC. A well-defined three-phase catalytic cycle was delineated, highlighting the role of domain rearrangements and phosphotransfer mediated by the conserved histidine residue H859. These findings enhance our understanding of HapC, with the potential to diversify prodiginine libraries and guide rational drug design.

Indexed as

Bacterial ProteinsProdigiosinMolecular Docking SimulationPyrrolesBacterial ProteinsprodiginineProdigiosinPyrrolesbiocontrol agentsdrug discoveryHahella chejuensisprodiginineprodigiosin

Identifiers

PMID41910414
PMCPMC13534948

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.